213 related articles for article (PubMed ID: 23403216)
1. siRNA delivery for the treatment of ovarian cancer.
Goldberg MS
Methods; 2013 Sep; 63(2):95-100. PubMed ID: 23403216
[TBL] [Abstract][Full Text] [Related]
2. Mesoporous silicon particles for sustained gene silencing.
Hasan N; Mann A; Ferrari M; Tanaka T
Methods Mol Biol; 2013; 1049():481-93. PubMed ID: 23913239
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of targets for ovarian cancer gene silencing therapy: in vitro and in vivo approaches.
Malek A; Tchernitsa O
Methods Mol Biol; 2010; 623():423-36. PubMed ID: 20217567
[TBL] [Abstract][Full Text] [Related]
4. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
5. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
6. [Research progress on the development of the strategies for siRNAs delivery in vivo].
Tang D; Mao A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Aug; 29(4):775-9. PubMed ID: 23016434
[TBL] [Abstract][Full Text] [Related]
7. Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells.
Palanca-Wessels MC; Booth GC; Convertine AJ; Lundy BB; Berguig GY; Press MF; Stayton PS; Press OW
Oncotarget; 2016 Feb; 7(8):9561-75. PubMed ID: 26840082
[TBL] [Abstract][Full Text] [Related]
8. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.
Urban-Klein B; Werth S; Abuharbeid S; Czubayko F; Aigner A
Gene Ther; 2005 Mar; 12(5):461-6. PubMed ID: 15616603
[TBL] [Abstract][Full Text] [Related]
9. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
10. Efficient inhibition of ovarian cancer by short hairpin RNA targeting claudin-3.
Sun C; Yi T; Song X; Li S; Qi X; Chen X; Lin H; He X; Li Z; Wei Y; Zhao X
Oncol Rep; 2011 Jul; 26(1):193-200. PubMed ID: 21519794
[TBL] [Abstract][Full Text] [Related]
11. Administration of PLGA nanoparticles carrying shRNA against focal adhesion kinase and CD44 results in enhanced antitumor effects against ovarian cancer.
Zou L; Song X; Yi T; Li S; Deng H; Chen X; Li Z; Bai Y; Zhong Q; Wei Y; Zhao X
Cancer Gene Ther; 2013 Apr; 20(4):242-50. PubMed ID: 23492823
[TBL] [Abstract][Full Text] [Related]
12. Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes.
Hossain S; Stanislaus A; Chua MJ; Tada S; Tagawa Y; Chowdhury EH; Akaike T
J Control Release; 2010 Oct; 147(1):101-8. PubMed ID: 20620182
[TBL] [Abstract][Full Text] [Related]
13. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
14. RNA interference (RNAi) in hematology.
Scherr M; Steinmann D; Eder M
Ann Hematol; 2004 Jan; 83(1):1-8. PubMed ID: 14574462
[TBL] [Abstract][Full Text] [Related]
15. Nanocarrier systems for delivery of siRNA to ovarian cancer tissues.
Fathabadi EG; Shelling AN; Al-Kassas R
Expert Opin Drug Deliv; 2012 Jul; 9(7):743-54. PubMed ID: 22657869
[TBL] [Abstract][Full Text] [Related]
16. Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines.
Numnum TM; Makhija S; Lu B; Wang M; Rivera A; Stoff-Khalili M; Alvarez RD; Zhu ZB; Curiel DT
Gynecol Oncol; 2008 Jan; 108(1):34-41. PubMed ID: 18061250
[TBL] [Abstract][Full Text] [Related]
17. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
Santel A; Aleku M; Keil O; Endruschat J; Esche V; Fisch G; Dames S; Löffler K; Fechtner M; Arnold W; Giese K; Klippel A; Kaufmann J
Gene Ther; 2006 Aug; 13(16):1222-34. PubMed ID: 16625243
[TBL] [Abstract][Full Text] [Related]
18. Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo.
Höbel S; Aigner A
Methods Mol Biol; 2010; 623():283-97. PubMed ID: 20217558
[TBL] [Abstract][Full Text] [Related]
19. SiRNA and epigenetic aberrations in ovarian cancer.
Mirzaei H; Yazdi F; Salehi R; Mirzaei HR
J Cancer Res Ther; 2016; 12(2):498-508. PubMed ID: 27461600
[TBL] [Abstract][Full Text] [Related]
20. Advances in synthetic siRNA delivery.
Manjunath N; Dykxhoorn DM
Discov Med; 2010 May; 9(48):418-30. PubMed ID: 20515610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
